Organization
Shanghai Juncell Therapeutics Co., Ltd., Shanghai, China
1 abstract
Abstract
A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer.Org: Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital, Shanghai, China, Shanghai Juncell Therapeutics Co., Ltd., Shanghai, China, Department of Radiology, Shanghai Tenth People's Hospital, Shanghai, China,